Generic drugs are less of a threat. The company has strong free cash flow growth, generating $2 billion in 2025, a strong balance sheet and return of invested capital of 24 per cent.
Paul Harris’s Top Picks for Nov. 24, 2025
view original post
Generic drugs are less of a threat. The company has strong free cash flow growth, generating $2 billion in 2025, a strong balance sheet and return of invested capital of 24 per cent.